keyword
MENU ▼
Read by QxMD icon Read
search

PEG-IFN

keyword
https://www.readbyqxmd.com/read/29328881/factors-affecting-the-virological-response-among-chronic-hepatitis-c-virus-patients-in-yemen
#1
Zaid Mutahar Mohammed Alezzi, Ayman Yosry Abd El Rehim, Waleed Fouad Fathallah, Mansour Ali Alamrani, Fouad Hezam Othman
Hepatitis C virus (HCV) infection is increasingly seen as a major public health problem, threat, and concern worldwide. In Yemen about 1.7% of the population is infected with chronic hepatitis C. This study aimed to detect the predictors for response to pegylated interferon and ribavirin (Peg-IFN/RBV) in chronic HCV Yemeni patients. The study was conducted on 100 patients with chronic HCV who received Peg-IFN/RBV in the 48th Military Hospital in Sana'a Yemen, from 2011 to 2013. All patients were subjected to complete history taking, thorough clinical examinations, routine laboratory investigation, and abdominal ultrasonography...
January 2018: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/29325289/-optimal-treatment-regimen-for-patients-with-hbeag-positive-chronic-hepatitis-b-after-suboptimal-response-to-24-weeks-of-peg-ifn-%C3%AE-2a
#2
X D Luo, X P Chen, X F Chen
Objective: To investigate the optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B (CHB) after suboptimal response to 24 weeks of pegylated interferon (Peg-IFN) α-2a. Methods: A total of 188 patients with HBeAg-positive CHB who had suboptimal response to 24 weeks of Peg-IFN α-2a were randomly divided into entecavir group (n = 93) and telbivudine group (n = 95). The two groups received entecavir 0.5 mg/d and telbivudine 0.6 g/d, respectively, for 208 weeks. After 208 weeks of treatment, the following indices were assessed: HBeAg clearance rate and seroconversion rate, hepatitis B virus (HBV) DNA clearance rate (HBV DNA < 500 IU/ml), safety, and drug resistance rate...
December 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29316059/cost-effectiveness-analyses-of-anti-hcv-treatments-using-qol-scoring-among-patients-with-chronic-liver-disease-in-the-hiroshima-prefecture
#3
Terumi Kaishima, Tomoyuki Akita, Masayuki Ohisa, Kazuaki Sakamune, Akemi Kurisu, Aya Sugiyama, Hiroshi Aikata, Kazuaki Cyayama, Junko Tanaka
AIM: We estimated the cost-effectiveness of direct acting antiviral treatment (DAA) compared to triple therapy (simeprevir, pegylated interferon-α and ribavirin) (scenario-1) and Peg-IFN+RBV(scenario-2) and non-antiviral therapy(scenario-3). METHODS: The Cost-effectiveness was evaluated as incremental cost-effectiveness ratios (ICERs) using direct costs and indirect costs which included loss of wages during the patient's lifetime due to early death caused by viral hepatitis infection...
January 5, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29314573/higher-efficacy-of-pegylated-interferon-alpha-2b-add-on-therapy-in-hbeag-positive-chronic-hepatitis-b-patients-on-tenofovir-monotherapy
#4
Ankur Jindal, Ashish Kumar Vyas, Devesh Kumar, Guresh Kumar, Manoj Kumar Sharma, Shiv Kumar Sarin
BACKGROUND: Monotherapy with Peg-IFNα or nucleos(t)ide analogues(NA) currently approved for treating chronic hepatitis B(CHB) have limited efficacy. Studies on combination of Peg-IFN-α/NA have shown conflicting results. We investigated whether sequential adding-on Peg-IFNα to tenofovir enhances serological response rates. METHODS: Treatment naïve, HBeAg-positive CHB patients with moderately elevated ALT(48 to 200IU/mL) were started on tenofovir(300 mg/day) and enrolled at week 12 in 1:1 ratio to either receive Peg-IFNα2b add-on(1...
January 4, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29303483/uptake-of-tenofovir-based-antiretroviral-therapy-among-hiv-hbv-coinfected-patients-in-the-eurosida-study
#5
Lars Peters, Amanda Mocroft, Daniel Grint, Santiago Moreno, Alexandra Calmy, Djordje Jevtovic, Helen Sambatakou, Karine Lacombe, Stephane De Wit, Jürgen Rockstroh, Jelena Smidt, Igor Karpov, Anna Grzeszczuk, Vesnadarjan Haziosmanovic, Magnus Gottfredsson, Roxana Radoi, Elena Kuzovatova, Chloe Orkin, Anna Lisa Ridolfo, Jose Zapirain, Jens Lundgren
BACKGROUND: According to guidelines all HIV/HBV co-infected patients should receive tenofovir-based combination antiretroviral therapy (cART). We aimed to investigate uptake and outcomes of tenofovir-based cART among HIV/HBV patients in the EuroSIDA study. METHODS: All HBsAg+ patients followed up after 1 March 2002 were included. Changes in the proportion taking tenofovir-based cART over time were described. Poisson regression was used to investigate the relationship between tenofovir use and clinical events...
January 5, 2018: Antiviral Therapy
https://www.readbyqxmd.com/read/29287014/treatment-of-chronic-hepatitis-c-virus-infection-in-children-a-position-paper-by-the-hepatology-committee-of-european-society-of-paediatric-gastroenterology-hepatology-and-nutrition
#6
Giuseppe Indolfi, Loreto Hierro, Antal Dezsofi, Jörg Jahnel, Dominique Debray, Nedim Hadzic, Piotr Czubowski, Girish Gupte, Yael Mozer-Glassberg, Wendy van der Woerd, Françoise Smets, Henkjan J Verkade, Björn Fischler
OBJECTIVES: In 2017, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) approved the use of the fixed-dose combination of ledipasvir/sofosbuvir and of the combination of sofosbuvir and ribavirin for treatment of adolescents (12-17 years, weighing more than 35 kg) with chronic hepatitis C virus (HCV) genotype 1, 4, 5 and 6 and genotype 2 and 3 infections, respectively. Although trials with direct acting antivirals (DAAs) are ongoing for younger children, the only available treatment in US and Europe for those < 12 years is still the dual therapy of pegylated interferon (PEG IFN) and ribavirin...
December 28, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29247529/serum-m2bpgi-level-is-a-novel-predictive-biomarker-for-the-responses-to-pegylated-interferon-%C3%AE-treatment-in-hbeag-positive-chronic-hepatitis-b-patients
#7
Ming-Yu Zhu, Pei-Zhan Chen, Jing Li, De-Min Yu, Dao Huang, Xue-Juan Zhu, Yue Han, Jie Chen, Wei Huang, Yong-Yan Chen, Qi-Ming Gong, Jie-Hong Jiang, Dong-Hua Zhang, Yan Zhang, Ji-Ming Zhang, Xin-Xin Zhang
Serum Mac-2-binding protein glycosylation isomer (M2BPGi) level was found to be a useful prognostic marker for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients treated with nucleoside/nucleotide analogs (NUCs) therapy, and the aim of our study is to evaluate the clinical implementation of M2BPGi level in the prediction of antiviral responses to pegylated-interferon-α (PEG-IFN-α) treatment in HBeAg-positive CHB patients. Ninety-six CHB patients who received PEG-IFN-α treatment for at least 48 weeks were recruited...
December 16, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/29225215/cognitive-impairment-with-interferon-treatment-in-patients-with-chronic-hepatitis-c
#8
Hiroto Tanaka, Hideyuki Sasaki
Interferon (IFN) has various side effects, including psychiatric symptoms. Event-related potentials are used as an electrophysiologic index of cognitive disorders. Auditory event-related potentials (P300) are often used in conditions in which cognitive ability is affected. In this study, we evaluated the association between P300, used to assess cognitive impairment, and neuropsychological side effects of IFN treatment in patients with chronic hepatitis C. Subjects were 20 patients with chronic hepatitis C; 13 patients were treated with peg IFN-α2b and ribavirin (riba group), and 7 patients were treated with peg IFN-α2a (alone group)...
2017: Biomedical Research
https://www.readbyqxmd.com/read/29201768/prediction-of-sustained-virological-response-to-peginterferon-based-therapy-for-chronic-hepatitis-c-regression-analysis-of-a-cohort-from-rio-grande-do-sul-brazil
#9
Rafael V Picon, Lúcia Fendt, Karine Amaral, Paulo D Picon
Aim: Peginterferon plus ribavirin (peg-IFN/RBV) is still the standard of care for treatment of hepatitis C virus (HCV) in many countries. Given the high toxicity of this regimen, our study aimed to develop a prediction tool that can identify which patients are unlikely to benefit from peg-IFN/RBV and could thus postpone treatment in favor of new-generation direct-acting antivirals. Materials and methods: Binary regression was performed using demographic, clinical, and laboratory covariates and sustained virological response (SVR) outcomes from a prospective cohort of individuals referred for therapy from 2003 to 2008 in a public HCV treatment center in Rio Grande do Sul, Brazil...
January 2017: Euroasian Journal of Hepato-Gastroenterology
https://www.readbyqxmd.com/read/29169329/micro-costing-analysis-of-guideline-based-treatment-by-direct-acting-agents-the-real-life-case-of-hepatitis-c-management-in-brazil
#10
Hugo Perazzo, Marcelino Jose Jorge, Julio Castro Silva, Alexandre Monken Avellar, Patrícia Santos Silva, Carmen Romero, Valdilea Gonçalves Veloso, Ruben Mujica-Mota, Rob Anderson, Chris Hyde, Rodolfo Castro
BACKGROUND: Eradication of hepatitis C virus (HCV) using direct-acting agents (DAA) has been associated with a financial burden to health authorities worldwide. We aimed to evaluate the guideline-based treatment costs by DAAs from the perspective of the Brazilian Ministry of Health (BMoH). METHODS: The activity based costing method was used to estimate the cost for monitoring/treatment of genotype-1 (GT1) HCV patients by the following strategies: peg-interferon (PEG-IFN)/ribavirin (RBV) for 48 weeks, PEG-IFN/RBV plus boceprevir (BOC) or telaprevir (TEL) for 48 weeks, and sofosbuvir (SOF) plus daclastavir (DCV) or simeprevir (SIM) for 12 weeks...
November 23, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/29168457/newer-direct-acting-antivirals-for-hepatitis-c-virus-infection-perspectives-for-india
#11
REVIEW
Varun Gupta, Ashish Kumar, Praveen Sharma, Anil Arora
Approximately three per cent of the world's population (170-200 million people) is chronically infected with hepatitis C virus (HCV) and almost 500,000 people die each year (mostly in lower middle-income countries) from complications secondary to HCV infection. In India, HCV infection imposes a considerable burden of mortality, morbidity and healthcare costs. In the last two decades, the treatment of HCV has evolved from interferon (IFN)-based therapies with or without ribavirin (RBV) to pegylated-IFN (PEG-IFN) and RBV-based therapies that were better tolerated by patients...
July 2017: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/29152762/optimizing-lonafarnib-treatment-for-the-management-of-chronic-delta-hepatitis-the-lowr-hdv-1-study
#12
Cihan Yurdaydin, Onur Keskin, Çağdaş Kalkan, Fatih Karakaya, Aysun Çalişkan, Ersin Karatayli, Senem Karatayli, A Mithat Bozdayi, Christopher Koh, Theo Heller, Ramazan Idilman, Jeffrey S Glenn
BACKGROUND AND RATIONALE: In a proof-of-concept (POC) study, the oral prenylation inhibitor lonafarnib (LNF) decreased HDV RNA during 4 weeks of treatment. Here we explored optimal LNF regimens. METHODS: 15 patients (5 groups; 3 per group) completed dosing as follows: 1) LNF 200 mg BID (12 weeks); 2) LNF 300 mg BID (12 weeks); 3) LNF 100 mg TID (5 weeks); 4) LNF 100 mg BID + pegylated interferon alfa (PEG-IFNα) 180 mcg QW (8 weeks); and 5) LNF 100 mg BID + ritonavir (RTV) 100 mg QD (8 weeks)...
November 20, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29152412/histomorphological-responses-after-therapy-with-pegylated-interferon-%C3%AE-2a-in-patients-with-essential-thrombocythemia-et-and-polycythemia-vera-pv
#13
Lucia Masarova, C Cameron Yin, Jorge E Cortes, Marina Konopleva, Gautam Borthakur, Kate J Newberry, Hagop M Kantarjian, Carlos E Bueso-Ramos, Srdan Verstovsek
Background: Pegylated interferon alfa-2a (PEG-IFN-α-2a) is a potent immunomodulating agent capable of inducing high rate of hematologic and even complete molecular remission in patients with essential thrombocythemia (ET) and polycythemia vera (PV). We recently reported results of a phase 2 trial of PEG-IFN-α-2a in 83 patients with ET and PV after a median follow-up of 83 months. Here we report an analysis of bone marrow (BM) responses in these patients. Methods: Among 83 patients, 58 (70%, PV 25, ET 31) had evaluable BM samples...
2017: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/29145802/effectiveness-of-current-and-future-regimens-for-treating-genotype-3-hepatitis-c-virus-infection-a-large-scale-systematic-review
#14
Hosnieh Fathi, Andrew Clark, Nathan R Hill, Geoffrey Dusheiko
BACKGROUND: Six distinct genetic variants (genotypes 1 - 6) of hepatitis C virus (HCV) exist globally. Certain genotypes are more prevalent in particular countries or regions than in others but, globally, genotype 3 (GT3) is the second most common. Patients infected with HCV GT1, 2, 4, 5 or 6 recover to a greater extent, as measured by sustained virological response (SVR), following treatment with regimens based on direct-acting antivirals (DAAs) than after treatment with older regimens based on pegylated interferon (Peg-IFN)...
November 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29142571/in-vitro-transcription-analysis-of-ns5a-from-hcv-3a-circulating-in-pakistani-patients-with-chronic-hepatitis-c-and-their-differential-response-to-antiviral-therapy
#15
Shameem Bhatti, Sobia Manzoor, Fahed Parvaiz, Javed Ashraf, Farakh Javed
Objective: Mutations in HCV nonstructural protein 5A (NS5A) play a vital role in virus resistance. The aim of this study was to develop a correlation between NS5A mutations (genotype 3a) and virological response towards interferon alpha (IFN-α) plus ribavirin therapy. Methods: In this study, which was conducted from 09-02-2013 to 25-11-2015 in the rural area of Province Sindh - Pakistan, total patients' responses to peg-IFN therapy were investigated. Patients were given peg-IFN therapy for 24 to 48 weeks and categorized as sustained virologic responders (SVR) or non-responders (NR) to HCV infection...
September 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29135370/pharmacokinetics-based-adjusted-versus-standard-dose-of-ribavirin-does-not-improve-virologic-response-rates-in-chronic-hepatitis-c-genotype-4-patients-a-randomized-controlled-trial
#16
Ibrahim H Altraif, Faisal Sanai, Mohammed A Babatin, Abduljaleel A Alalwan, Ayman A Abdo, Waleed Alhamoudi, Musthafa Peedikayil, Hamdan Alghamdi, Fahad Alsohaibani, Khalid A Alswat, Shazia Murtaza, Abdullah Alghamdi, Sara Altraif, Abdulrahman Aljumah, Fayaz A Handoo, Abdulkareem M AlBekairy, Hamad I Al-Ashgar, Mohammed Alquaiz, Mohammed A Alblawi, Waleed AlTamimi, Véronique Loustaud-Ratti, Pierre Marquett
Optimal doses of Ribavirin (RBV) for hepatitis C virus (HCV) treatment are not known. To assess the safety and efficacy of PegIFNalfa-2a in combination with an adjusted (ADJ) RBV dose based on early pharmacokinetics versus a fixed standard (STD) dose of RBV in chronic HCV genotype (GT) 4-naive patients in a randomized trial. One hundred eighty-one patients were randomized. The baseline variables were similar in both arms and females were 50.3% of the patients, 76.5% had minimal-moderate fibrosis (F0-2). Sustained virologic response (SVR) was achieved in 99 (54...
November 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/29119253/higher-expression-of-inhibitory-cd158b-and-cd158e-nk-cell-receptor-and-age-predicts-treatment-response-in-children-with-chronic-hepatitis-c
#17
Anna Mania, Mariusz Kaczmarek, Paweł Kemnitz, Katarzyna Mazur-Melewska, Magdalena Figlerowicz, Jan Sikora, Wojciech Służewski, Jan Żeromski
Treatment with pegylated interferon-α and ribavirin (PEG-IFN/RBV) is the only choice for chronic hepatitis C (CHC) in children. Natural killer (NK) cells were described to play a vital role in CHC. The aim of this study was to analyze the expression of peripheral blood NK cell receptors in their relation to PEG-IFN/RBV treatment response. Study included 26 children with CHC-13 boys, age range 13.42 ± 3.28 years. Blood for biochemical, virological and cytometric testing was taken for evaluation prior to the antiviral treatment...
November 8, 2017: Medical Microbiology and Immunology
https://www.readbyqxmd.com/read/29116287/peginterferon-still-has-a-place-in-the-treatment-of-hepatitis-c-caused-by-genotype-3-virus
#18
Aline Vitali Grando, Paulo Roberto Abrão Ferreira, Mário Guimarães Pessôa, Daniel Ferraz de Campos Mazo, Carlos Eduardo Brandão-Mello, Tânia Reuter, Ana de Lourdes Candolo Martinelli, Mário Peribanez Gonzalez, Ana Catharina Seixas-Santos Nastri, Aléia Faustina Campos, Max Igor Banks Ferreira Lopes, José David Urbaez Brito, Maria Cássia Mendes-Corrêa
Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) indicators and early treatment interruption due to serious adverse events (SAE). This was a retrospective observational study of GEN3/CHC patients, co-infected or not by HIV and treated with Peg-IFN/RBV in nine Brazilian healthcare centers...
November 6, 2017: Revista do Instituto de Medicina Tropical de São Paulo
https://www.readbyqxmd.com/read/29097076/the-treatment-outcome-and-impact-on-blood-transfusion-demand-of-peg-interferon-ribavirin-in-thalassemic-patients-with-chronic-hepatitis-c
#19
Po-Cheng Liang, Pei-Chin Lin, Ching-I Huang, Chung-Feng Huang, Ming-Lun Yeh, Yu-Sheng Zeng, Wan-Yi Hsu, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Shyh-Shin Chiou, Ming-Lung Yu
BACKGROUND/AIMS: Hepatitis C virus (HCV) prevails in patients with thalassemia. We aimed to investigate the efficacy, safety, and impact on red blood cells (RBC) transfusion demand of pegylated interferon (Peg-IFN)/ribavirin therapy in thalassemic patients with HCV. METHODS: This retrospective study included 18 thalassemic patients (16 with HCV-1b, one HCV-1b/2b, and one HCV-2b) and 54 consecutive sex- and genotype-matched controls. Patients with HCV-2, or HCV-1 or mixed HCV-1/2 with lower viral loads plus rapid virological response (RVR) received 24-week Peg-IFN/ribavirin; whereas HCV-1 or mixed HCV-1/2 with higher viral loads or without RVR received 48-week regimens...
October 30, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29091327/unconventional-t-cells-in-chronic-hepatitis-b-patients-on-long-term-suppressive-therapy-with-tenofovir-followed-by-a-peg-ifn-add-on-strategy-a-randomized-study
#20
Elvira Stefania Cannizzo, Camilla Tincati, Francesca Binda, Paola Ronzi, Federico Angelo Cazzaniga, Spinello Antinori, Antonella d'Arminio Monforte, Giulia Marchetti, Laura Milazzo
HBV eradication in Chronic Hepatitis B (CHB) subjects is rarely achieved with either nucleos(t)ide analogues (NA) or pegylated interferon (Peg-IFN), which both have a limited effect in restoring immune responses. 30 CHB subjects on long-term treatment with tenofovir (TDF) and HBV suppression were enrolled and randomized 1:2 to either receive Peg-IFN-α-2a add-on therapy or continue TDF alone. We studied γδT and iNKT frequency and function (by flow cytometry) at baseline, at 12 weeks and 12 weeks after the end of treatment...
November 1, 2017: Journal of Viral Hepatitis
keyword
keyword
31627
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"